US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
AU724042B2
(en)
*
|
1996-10-25 |
2000-09-07 |
Minnesota Mining And Manufacturing Company |
Immune response modifier compounds for treatment of TH2 mediated and related diseases
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
SK287112B6
(sk)
|
1999-01-08 |
2009-12-07 |
3M Innovative Properties Company |
Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6756382B2
(en)
*
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6677348B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6545017B1
(en)
*
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
AU2002232498B2
(en)
*
|
2000-12-08 |
2006-05-04 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
JP2005501550A
(ja)
*
|
2001-08-30 |
2005-01-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
|
EP1478371A4
(en)
*
|
2001-10-12 |
2007-11-07 |
Univ Iowa Res Found |
METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND
|
DK1719511T3
(da)
*
|
2001-11-16 |
2009-04-14 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
|
AU2002363954B2
(en)
*
|
2001-11-29 |
2008-04-03 |
3M Innovative Properties Company |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
*
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
WO2003072026A2
(en)
*
|
2002-02-22 |
2003-09-04 |
3M Innovative Properties Company |
Method of reducing and treating uvb-induced immunosuppression
|
AU2003216851B2
(en)
*
|
2002-03-19 |
2008-04-17 |
Powderject Research Limited |
Imidazoquinoline adjuvants for vaccines
|
AU2003216852B2
(en)
*
|
2002-03-19 |
2008-09-11 |
Glaxo Group Limited |
Imidazoquinolineamines as adjuvants in HIV DNA vaccination
|
ES2734652T3
(es)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Oligorribonucleótidos inmunoestimulantes que contienen G y U
|
BR0311648A
(pt)
*
|
2002-06-07 |
2005-04-19 |
3M Innovative Properties Co |
Imidazopiridinas substituìdas por éter
|
US7427629B2
(en)
|
2002-08-15 |
2008-09-23 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
WO2004028539A2
(en)
*
|
2002-09-26 |
2004-04-08 |
3M Innovative Properties Company |
1h-imidazo dimers
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003287324A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
WO2004058759A1
(en)
|
2002-12-20 |
2004-07-15 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
EP1592302A4
(en)
*
|
2003-02-13 |
2007-04-25 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
AU2004218349A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
CA2517655A1
(en)
*
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
EP1603510B1
(en)
*
|
2003-03-13 |
2012-05-09 |
3M Innovative Properties Company |
Methods of improving skin quality
|
JP2006523212A
(ja)
*
|
2003-03-13 |
2006-10-12 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚病変の診断方法
|
JP2006520245A
(ja)
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
EP1615665A4
(en)
*
|
2003-04-10 |
2010-10-06 |
3M Innovative Properties Co |
DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
US6943255B2
(en)
*
|
2003-06-06 |
2005-09-13 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
US20050032829A1
(en)
*
|
2003-06-06 |
2005-02-10 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
KR20060056354A
(ko)
*
|
2003-07-31 |
2006-05-24 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
트리아진을 포함하는 생체활성 조성물
|
CA2534625A1
(en)
*
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
MXPA06001674A
(es)
*
|
2003-08-12 |
2006-05-12 |
3M Innovative Properties Co |
Compuestos que contienen imidazo hidroxilamina-sustituidos.
|
EP2939693A1
(en)
*
|
2003-08-14 |
2015-11-04 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
JP2007503268A
(ja)
*
|
2003-08-25 |
2007-02-22 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾化合物の送達
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
JP5128815B2
(ja)
*
|
2003-08-27 |
2013-01-23 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールオキシ置換およびアリールアルキレンオキシ置換イミダゾキノリン
|
US20060216333A1
(en)
*
|
2003-09-02 |
2006-09-28 |
Miller Richard L |
Methods related to the treatment of mucosal associated conditions
|
US20050054665A1
(en)
*
|
2003-09-05 |
2005-03-10 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
JP2007505629A
(ja)
*
|
2003-09-17 |
2007-03-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Tlr遺伝子発現の選択的調節
|
KR101494056B1
(ko)
|
2003-10-03 |
2015-02-16 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피라졸로피리딘 및 그의 유사체
|
EP1673087B1
(en)
*
|
2003-10-03 |
2015-05-13 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
US20050096259A1
(en)
*
|
2003-10-31 |
2005-05-05 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
CA2545825A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
WO2005048933A2
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
EP1686992A4
(en)
*
|
2003-11-25 |
2009-11-04 |
3M Innovative Properties Co |
HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
|
RU2409576C2
(ru)
|
2003-11-25 |
2011-01-20 |
3М Инновейтив Пропертиз Компани |
Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
AU2004315771A1
(en)
*
|
2003-12-04 |
2005-08-25 |
3M Innovative Properties Company |
Sulfone substituted imidazo ring ethers
|
EP1699792A1
(en)
*
|
2003-12-29 |
2006-09-13 |
3M Innovative Properties Company |
Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
|
JP2007517035A
(ja)
*
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
JP2007517055A
(ja)
*
|
2003-12-30 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答の増強
|
CA2551399A1
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
US20070167479A1
(en)
*
|
2004-03-15 |
2007-07-19 |
Busch Terri F |
Immune response modifier formulations and methods
|
WO2005094531A2
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
AU2005244260B2
(en)
*
|
2004-04-09 |
2010-08-05 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
MXPA06012451A
(es)
*
|
2004-04-28 |
2007-01-31 |
3M Innovative Properties Co |
Composiciones y metodos para vacunacion por la mucosa.
|
WO2006078294A2
(en)
|
2004-05-21 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus vectors for respiratory pathogen vaccines
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
WO2005123079A2
(en)
*
|
2004-06-14 |
2005-12-29 |
3M Innovative Properties Company |
Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7897609B2
(en)
*
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
JP5128940B2
(ja)
*
|
2004-06-18 |
2013-01-23 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US8541438B2
(en)
*
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
WO2006026760A2
(en)
*
|
2004-09-02 |
2006-03-09 |
3M Innovative Properties Company |
1-amino imidazo-containing compounds and methods
|
ES2384390T3
(es)
*
|
2004-09-02 |
2012-07-04 |
3M Innovative Properties Company |
Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados
|
AU2005282523A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1H imidazo ring systems and methods
|
US20080193468A1
(en)
*
|
2004-09-08 |
2008-08-14 |
Children's Medical Center Corporation |
Method for Stimulating the Immune Response of Newborns
|
CA2580343A1
(en)
*
|
2004-09-14 |
2006-03-23 |
Novartis Vaccines And Diagnostics, Inc. |
Imidazoquinoline compounds
|
US20070243215A1
(en)
*
|
2004-10-08 |
2007-10-18 |
Miller Richard L |
Adjuvant for Dna Vaccines
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US8080560B2
(en)
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
SI1830876T1
(sl)
|
2004-12-30 |
2015-08-31 |
Meda Ab |
Uporaba imikvimoda za zdravljenje kožnih metastaz, ki izhajajo iz rakavega tumorja dojke
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
EP1831226B1
(en)
*
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Chiral tetracyclic compounds inducing interferon biosynthesis
|
CA2594674C
(en)
*
|
2004-12-30 |
2016-05-17 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
AR052447A1
(es)
*
|
2004-12-30 |
2007-03-21 |
3M Innovative Properties Co |
Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
|
JP2008530022A
(ja)
*
|
2005-02-04 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫反応調節物質を含む水性ゲル処方物
|
CA2597324C
(en)
|
2005-02-09 |
2015-06-30 |
Coley Pharmaceutical Group, Inc. |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2007120121A2
(en)
|
2005-02-09 |
2007-10-25 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
|
AU2006213745A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
|
US7968563B2
(en)
|
2005-02-11 |
2011-06-28 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
CA2597446A1
(en)
*
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
NZ560929A
(en)
|
2005-02-18 |
2009-12-24 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
NZ597685A
(en)
|
2005-02-18 |
2013-12-20 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
AU2006216799A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006098852A2
(en)
*
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
EP1851218A2
(en)
*
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
US8846710B2
(en)
*
|
2005-02-23 |
2014-09-30 |
3M Innovative Properties Company |
Method of preferentially inducing the biosynthesis of interferon
|
BRPI0608011A2
(pt)
|
2005-03-14 |
2009-11-03 |
Graceway Pharmaceuticals Llc |
uso de uma formulação para o tratamento da queratose actìnica e uso de 2-metil-1-(2-metilpropil)-1h-imidazo[4,5-c][1,5] naftiridin-4-amina
|
US7943610B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
EP1863814A1
(en)
|
2005-04-01 |
2007-12-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
WO2007030775A2
(en)
*
|
2005-09-09 |
2007-03-15 |
Coley Pharmaceutical Group, Inc. |
Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
AU2006310336B2
(en)
|
2005-11-04 |
2011-02-03 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2628131C
(en)
*
|
2005-11-04 |
2012-03-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
|
ATE539765T1
(de)
|
2005-11-04 |
2012-01-15 |
Novartis Vaccines & Diagnostic |
Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
|
EP1951298A1
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
KR20080089663A
(ko)
|
2006-01-27 |
2008-10-07 |
노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
US8329721B2
(en)
*
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
WO2007106852A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
|
EP2007765B1
(en)
*
|
2006-03-23 |
2012-06-27 |
Novartis AG |
Immunopotentiating compounds
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
EP2357184B1
(en)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
WO2008020335A2
(en)
|
2006-06-09 |
2008-02-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
WO2008008432A2
(en)
*
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
US8178539B2
(en)
*
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
CA2663196A1
(en)
|
2006-09-11 |
2008-03-20 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
JP2010531348A
(ja)
|
2007-06-27 |
2010-09-24 |
ノバルティス アーゲー |
添加剤の少ないインフルエンザワクチン
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
WO2009034473A2
(en)
|
2007-09-12 |
2009-03-19 |
Novartis Ag |
Gas57 mutant antigens and gas57 antibodies
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8940771B2
(en)
|
2007-12-20 |
2015-01-27 |
Novartis Ag |
Organic compounds
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN101977926B
(zh)
|
2007-12-21 |
2014-10-08 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
CA2718430A1
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
CN101717397B
(zh)
*
|
2008-10-09 |
2012-11-28 |
中国科学院上海药物研究所 |
一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
CN103800906B
(zh)
|
2009-03-25 |
2017-09-22 |
德克萨斯大学系统董事会 |
用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
|
SI2510947T1
(sl)
|
2009-04-14 |
2016-05-31 |
Glaxosmithkline Biologicals S.A. |
Sestavki za imunizacijo proti Staphylococcus aureus
|
USH2283H1
(en)
|
2009-04-27 |
2013-09-03 |
Novartis Ag |
Vaccines for protecting against influenza
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
ES2918381T3
(es)
|
2009-07-15 |
2022-07-15 |
Glaxosmithkline Biologicals Sa |
Composiciones de proteína F de VRS y métodos para producir las mismas
|
SI2464658T1
(sl)
|
2009-07-16 |
2015-02-27 |
Novartis Ag |
Detoksificirani imunogeni escherichie coli
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
CA2808624C
(en)
|
2010-08-17 |
2019-05-14 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
LT2667892T
(lt)
|
2011-01-26 |
2019-05-10 |
Glaxosmithkline Biologicals Sa |
Rsv imunizacijos režimas
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
SI2707385T1
(en)
|
2011-05-13 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Pregnant RSV F antigens
|
WO2012167088A1
(en)
|
2011-06-03 |
2012-12-06 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
EP3366311B1
(en)
|
2011-06-03 |
2020-02-26 |
3M Innovative Properties Co. |
Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
SG11201401716XA
(en)
|
2011-10-28 |
2014-05-29 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
CA2871711A1
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
RU2630975C2
(ru)
|
2012-05-16 |
2017-09-15 |
Новартис Аг |
Режим дозирования pi-3 киназы
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
RU2669941C2
(ru)
|
2013-01-07 |
2018-10-17 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы для лечения t-клеточной лимфомы кожи
|
CA2904507C
(en)
|
2013-03-10 |
2021-05-04 |
Peritech Pharma Ltd. |
Topical compositions and methods of treatment of topical disorders
|
EP3632458A1
(en)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
US11020486B2
(en)
|
2013-11-05 |
2021-06-01 |
3M Innovative Properties Company |
Sesame oil based injection formulations
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
SI3076969T1
(sl)
|
2013-12-06 |
2021-12-31 |
Novartis Ag |
Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
|
EP3092254A4
(en)
|
2014-01-10 |
2017-09-20 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating her2 positive tumors
|
WO2015108595A1
(en)
|
2014-01-15 |
2015-07-23 |
Nikolai Khodarev |
Anti-tumor therapy
|
CN106103469B
(zh)
|
2014-03-26 |
2020-11-27 |
葛兰素史密丝克莱恩生物有限公司 |
突变型葡萄球菌抗原
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
CA3002954A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
CA3034553A1
(en)
*
|
2016-08-26 |
2018-03-01 |
3M Innovative Properties Company |
Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
AU2017356673B2
(en)
|
2016-11-09 |
2023-11-09 |
Pulmotect, Inc. |
Methods and compositions for adaptive immune modulation
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
WO2018232725A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
CA3086439A1
(en)
|
2017-12-20 |
2019-06-27 |
3M Innovative Properties Company |
Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
CN112513070A
(zh)
|
2018-02-28 |
2021-03-16 |
辉瑞公司 |
Il-15变体及其用途
|
KR102584675B1
(ko)
|
2018-05-23 |
2023-10-05 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
WO2021124073A1
(en)
|
2019-12-17 |
2021-06-24 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|